Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06535815

KetoNiFast: Cyclic Enteral Daytime Feeding With Ketogenic Nighttime Fasting

A physiological human nutrition includes circadian feeding and nighttime fasting during sleep. There is increasing evidence, that this natural fasting episode over nighttime majorly contributes to repair processes of the human body. So far, intensive care patients are normally enterally fed continuously, so that there is no circadian nutrition and no nighttime fasting. An enteral nutrition for 12 hours followed by a fasting period of 12 hours supported by exogenous ketone salts potentially improves the reconstitution of ICU patients compared to ICU patients who are continuously enterally fed.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Department of Anesthesiology and Intensive Care Medicine

Cologne, North Rhine-Westphalia, 50937, Germany

Location status: Recruiting

Location contact

Sandra E Stoll, MD

CONTACT

[email protected]

+491735697566

Sandra E Stoll, MD

CONTACT

[email protected]

+491735697566 ext. Stoll

Sandra E Stoll, MD

PRINCIPAL_INVESTIGATOR

About this study

There is increasing evidence that a circadian rhythm of feeding (cyclic feeding) could be beneficial for critical ill patients. Cyclic feeding and fasting are assumed to have positive effects on the gut microbiome resulting in optimization of host responses to gastrointestinal pathogens. Another positive effect of cyclic feeding potentially results from activation of a "fasting response", inducing repair pathways such as ketogenesis, mitochondrial biogenesis, anti-inflammatory pathways, antioxidant defenses and autophagy processes. The activation of these repair pathways could diminish cellular stress and promote cellular recovery in critical ill patients. A randomized controlled trial by van Dyck et al. could show that fasting-mimicking intervals of 12 hours are sufficient to generate a metabolic fasting response without risking a caloric deficit. This fasting response can be enhanced by additional supplementation of exogenous ketones. A cyclic enteral nutrition with 12 hours of daytime feeding and 12 hours of ketogenic nighttime fasting compared to a continuous enteral feeding for 24 hours can potentially improve the reconstitution of critically ill Intensive Care patients. This improved reconstitution can be measured by maintenance of muscle mass (measured by ultrasound of the musculus rectus femoris), urea/creatinine ration, length of ventilation, length of ICU and hospital stay, 30-day mortality, ICU mobility scale.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • written informed consent to participate in this study
  • admission to ICU
  • enteral nutrition

Exclusion criteria

  • Severe liver dysfunction / liver failure (Child Pugh >7 points / category B)
  • Severe kidney dysfunction (KDIGO stage 3)
  • Total pancreatectomy / insulin dependent diabetes mellitus (IDDM)
  • Pregnancy / lactation
  • Hemoglobin concentration < 80g/l
  • Severe metabolic disorders / severe autoimmune diseases
  • Refractory metabolic or respiratory acidosis
  • Dysfunction of mitochondrial transport of fatty acids
  • Dysfunction of oxidation of fatty acids
  • Dysfunction of gluconeogenesis, production and reduction of ketones
  • Intermittent Porphyria
  • Severe cardiac arrhythmias / cardiomyopathy
  • Contraindication against enteral nutrition
  • Lack of informed consent

Treatment and study plan

Cyclic enteral feeding with nighttime fasting and exogenous ketone salt supplementation (ß-hydroxybutyrate)

Other

12 hours of enteral feeding (as per patients´individual calorimetric requirements measured by indirect calorimetry) followed by a fasting period of 12 hours supported by the supplementation of exogenous ketone salts.

Other names: cyclic nutrition with nighttime fasting and exogenous ß-hydroxybutyrate supplementation

Primary outcomes

  1. Loss of muscle mass

    Time frame: From date of randomization until the date of ICU discharge up to 1 month

    Loss of muscle mass via Ultrasound of M. rectus femoris of a predefined leg

  2. Progress of urea / creatinine ratio

    Time frame: From date of randomization until the date of ICU discharge up to 1 month

    Urea / creatinine ratio in the patients´ blood

Secondary outcomes

  1. Length of invasive and noninvasive ventilation

    Time frame: From date of randomization until the date of ICU discharge up to 1 month

    Length of invasive and noninvasive ventilation

  2. Length of ICU and hospital stay

    Time frame: From date of randomization until the date of hospital discharge up to 6 months

    Length of ICU and hospital stay

  3. 30 day mortality on day 30

    Time frame: From date of randomization 30 days

    30 day mortality on day 30

  4. ICU mobility scale on discharge

    Time frame: From date of randomization until the date of ICU discharge up to 1 month

    ICU mobility scale (lowest score 0, highest score 10)

Study contacts

Contact information is provided by the study sponsor or research team.

Fabian Dusse, PD, MD

CONTACT

[email protected]

+49221478 ext. 40806

Sandra E Stoll, MD, assProf.

CONTACT

[email protected]

+49221478 ext. 82054

Sponsors and collaborators

Lead sponsor

University Hospital of Cologne

Other

Registry information

Official study title

KetoNiFast: Impact of Cyclic Enteral Daytime Feeding With Ketogenic Nighttime Fasting on Outcome of Critical Ill Patients.

Acronym: KetoNiFast

Important dates

Study start
2023
Primary completion
2025
Study completion
2026
First posted
Aug 2, 2024
Registry last updated
Aug 6, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.